EBS:NYSE
Emergent Biosolutions Inc
6,93 $
arrow_upward
+0,36%(+0,025) 1D
15 հոկ, 09:39:35 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
6,92 $
High
7,01 $
Low
6,92 $
Mkt. cap
355,32 մլն
Avg. vol.
1,13 մլն
Volume
4,18 հզր
52-wk high
14,06 $
52-wk low
4,36 $
EPS
-3,51 $
Beta
2,28
Shares outstanding
51,27 մլն
No. of employees
900
Open
6,92 $
High
7,01 $
Low
6,92 $
Mkt. cap
355,32 մլն
Avg. vol.
1,13 մլն
Volume
4,18 հզր
52-wk high
14,06 $
52-wk low
4,36 $
EPS
-3,51 $
Beta
2,28
Shares outstanding
51,27 մլն
No. of employees
900
News stories
From web sources and news partners
Business Wire
·
1 ժամ առաջ
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
Founded05 սեպ, 1998 թ.
HeadquartersRockville, Մերիլենդ, Միացյալ Նահանգներ
Sector-
Websiteemergentbiosolutions.com